MeSH term
Frequency | Condition_Probility | Adult | 57 | 0.0 |
Comparative Study | 36 | 0.0 |
Humans | 361 | 0.0 |
Aged | 33 | 0.0 |
Time Factors | 7 | 0.0 |
Alleles | 100 | 1.0 |
Genes, Wilms Tumor | 4 | 6.0 |
Genomic Imprinting/*genetics | 27 | 35.0 |
Glycoproteins/*genetics | 2 | 1.0 |
Heterozygote | 25 | 0.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Kidney Neoplasms/*genetics/pathology | 7 | 9.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Neoplasm Proteins/*genetics | 3 | 0.0 |
Nephroblastoma/*genetics/pathology | 4 | 14.0 |
Polymorphism, Genetic/genetics | 4 | 0.0 |
Proteins/genetics | 11 | 1.0 |
RNA, Neoplasm/analysis | 6 | 2.0 |
Research Support, Non-U.S. Gov't | 268 | 0.0 |
Child, Preschool | 21 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 9 | 3.0 |
Gene Expression Regulation, Neoplastic | 28 | 1.0 |
Immunohistochemistry | 11 | 0.0 |
*Loss of Heterozygosity | 5 | 1.0 |
Male | 154 | 0.0 |
Proteins/*genetics | 5 | 0.0 |
RNA, Untranslated/*genetics | 16 | 32.0 |
Up-Regulation | 5 | 0.0 |
*Alleles | 16 | 1.0 |
Animals | 132 | 0.0 |
Cells, Cultured | 19 | 0.0 |
*DNA Methylation | 25 | 3.0 |
Female | 176 | 0.0 |
*Gene Expression | 10 | 0.0 |
Genes, Tumor Suppressor | 7 | 0.0 |
*Genomic Imprinting | 104 | 36.0 |
Insulin-Like Growth Factor II/genetics | 49 | 62.0 |
Mice | 91 | 0.0 |
Mice, Inbred C57BL | 13 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 110 | 0.0 |
Ribonucleoproteins, Small Nuclear/genetics | 4 | 28.0 |
Acetylation | 3 | 0.0 |
Base Sequence | 79 | 0.0 |
Cell Division | 6 | 0.0 |
DNA/genetics | 6 | 0.0 |
DNA Methylation | 39 | 5.0 |
DNA-Binding Proteins/*genetics | 4 | 0.0 |
Gene Expression | 35 | 0.0 |
Genomic Imprinting | 42 | 23.0 |
*Mutation | 7 | 0.0 |
Phenotype | 21 | 0.0 |
*Repressor Proteins | 11 | 0.0 |
Down-Regulation | 4 | 0.0 |
Genomic Imprinting/genetics | 6 | 35.0 |
Middle Aged | 48 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 4 | 2.0 |
RNA, Messenger/metabolism | 12 | 0.0 |
Reference Values | 3 | 0.0 |
Aged, 80 and over | 15 | 0.0 |
Body Mass Index | 3 | 0.0 |
Genotype | 28 | 0.0 |
Homozygote | 4 | 0.0 |
Insulin-Like Growth Factor II/analysis/*genetics | 3 | 60.0 |
3' Untranslated Regions | 2 | 1.0 |
Binding Sites | 7 | 0.0 |
Chromatin/metabolism | 3 | 1.0 |
Conserved Sequence | 5 | 0.0 |
Evolution, Molecular | 4 | 0.0 |
Insulin-Like Growth Factor II/*genetics | 117 | 79.0 |
Molecular Sequence Data | 78 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
*Apoptosis | 2 | 0.0 |
Fibroblasts/*metabolism | 3 | 1.0 |
Flow Cytometry | 3 | 0.0 |
Lymphocytes/metabolism | 5 | 2.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Signal Transduction | 5 | 0.0 |
Adolescent | 16 | 0.0 |
Child | 36 | 0.0 |
Gene Expression Profiling | 7 | 0.0 |
Oligonucleotide Array Sequence Analysis | 6 | 0.0 |
Prognosis | 4 | 0.0 |
Polymorphism, Genetic | 26 | 0.0 |
Promoter Regions (Genetics) | 23 | 0.0 |
RNA, Messenger/analysis | 11 | 0.0 |
DNA, Complementary | 5 | 0.0 |
*Disease Models, Animal | 2 | 0.0 |
RNA, Untranslated/genetics | 11 | 37.0 |
Rats | 26 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Case-Control Studies | 5 | 0.0 |
CpG Islands/genetics | 4 | 2.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Body Weight/*genetics | 2 | 13.0 |
Chromosome Mapping | 32 | 0.0 |
Diabetes Mellitus, Type 1/genetics | 2 | 5.0 |
Genetic Markers | 8 | 0.0 |
Insulin/genetics | 6 | 20.0 |
Linkage (Genetics) | 11 | 0.0 |
Minisatellite Repeats | 3 | 2.0 |
Polymorphism, Restriction Fragment Length | 22 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Amino Acid Sequence | 16 | 0.0 |
*Gene Expression Regulation, Neoplastic | 14 | 0.0 |
*Gene Silencing | 4 | 2.0 |
Gene Targeting | 2 | 0.0 |
*Genes, Tumor Suppressor | 10 | 0.0 |
Tumor Cells, Cultured | 28 | 0.0 |
Autoantigens/genetics | 5 | 14.0 |
Binding Sites/genetics | 3 | 0.0 |
Gene Expression Regulation/*genetics | 2 | 1.0 |
In Situ Hybridization, Fluorescence | 9 | 0.0 |
*Ribonucleoproteins, Small Nuclear | 4 | 7.0 |
Transcription, Genetic/*genetics | 3 | 1.0 |
Cell Line | 17 | 0.0 |
Cloning, Molecular | 11 | 0.0 |
*CpG Islands | 2 | 2.0 |
Potassium Channels/*genetics | 5 | 3.0 |
*Potassium Channels, Voltage-Gated | 10 | 3.0 |
Restriction Mapping | 6 | 0.0 |
*Conserved Sequence | 2 | 1.0 |
*Enhancer Elements (Genetics) | 5 | 1.0 |
Gene Silencing | 5 | 1.0 |
Transcription, Genetic | 19 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Insulin-Like Growth Factor II/*genetics/metabolism | 9 | 60.0 |
*Promoter Regions (Genetics) | 16 | 0.0 |
*Transcription, Genetic | 6 | 0.0 |
Chromosomes, Human, Pair 11 | 23 | 6.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Gene Frequency | 7 | 0.0 |
*Linkage (Genetics) | 7 | 0.0 |
Lod Score | 4 | 0.0 |
Microsatellite Repeats | 5 | 0.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 8 | 3.0 |
Insulin/*genetics | 15 | 24.0 |
Sex Factors | 2 | 0.0 |
Mice, Transgenic | 9 | 0.0 |
Organ Specificity | 9 | 0.0 |
*Variation (Genetics) | 4 | 0.0 |
DNA Primers/chemistry | 4 | 0.0 |
Hepatoblastoma/*genetics | 9 | 52.0 |
Infant | 21 | 0.0 |
Liver/metabolism | 3 | 0.0 |
Liver Neoplasms/*genetics/metabolism | 5 | 19.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 21 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 2 | 1.0 |
DNA Primers | 27 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Histones/metabolism | 2 | 0.0 |
Hydroxamic Acids/pharmacology | 3 | 1.0 |
Polymerase Chain Reaction | 55 | 0.0 |
Pregnancy | 28 | 0.0 |
Transfection | 6 | 0.0 |
Carcinoma, Hepatocellular/*genetics | 7 | 8.0 |
Liver Neoplasms/*genetics | 16 | 14.0 |
Loss of Heterozygosity | 13 | 1.0 |
DNA/metabolism | 5 | 0.0 |
Family Health | 4 | 0.0 |
Genes, Dominant | 4 | 0.0 |
Mutation | 10 | 0.0 |
Pedigree | 17 | 0.0 |
5' Untranslated Regions/genetics | 2 | 1.0 |
Antigens, Polyomavirus Transforming/*genetics | 3 | 11.0 |
Gene Expression Regulation, Neoplastic/genetics | 3 | 1.0 |
Liver/physiology | 3 | 5.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Gene Expression Regulation | 12 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
Transcription Factors/*metabolism | 5 | 0.0 |
DNA Mutational Analysis | 5 | 0.0 |
Models, Biological | 6 | 0.0 |
*Chromosome Mapping | 10 | 0.0 |
Tyrosine 3-Monooxygenase/*genetics | 2 | 1.0 |
*DNA Footprinting | 2 | 25.0 |
Evolution | 4 | 1.0 |
*RNA, Untranslated | 65 | 34.0 |
Regulatory Sequences, Nucleic Acid | 5 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Azacitidine/pharmacology | 2 | 4.0 |
DNA, Neoplasm | 3 | 2.0 |
In Situ Hybridization/methods | 2 | 1.0 |
Neoplasm Transplantation | 3 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 3 | 1.0 |
Head and Neck Neoplasms/*genetics | 2 | 2.0 |
Nerve Tissue Proteins/genetics | 2 | 0.0 |
Nuclear Proteins/genetics | 8 | 2.0 |
Cohort Studies | 5 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
*Minisatellite Repeats | 2 | 2.0 |
Obesity/*genetics | 3 | 2.0 |
*Multigene Family | 3 | 0.0 |
*Translocation, Genetic | 3 | 0.0 |
English Abstract | 8 | 0.0 |
Genes, Tumor Suppressor/*genetics | 7 | 2.0 |
Genes, Wilms Tumor/genetics | 3 | 13.0 |
Apoptosis | 2 | 0.0 |
Biological Markers | 3 | 0.0 |
Cell Differentiation | 3 | 0.0 |
Chromogranins/analysis | 2 | 3.0 |
Insulin-Like Growth Factor II/analysis | 2 | 22.0 |
Neoplasm Proteins/analysis | 2 | 0.0 |
3' Untranslated Regions/genetics | 2 | 2.0 |
*Body Mass Index | 3 | 3.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 5 | 3.0 |
Linkage Disequilibrium | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Sequence Alignment | 8 | 0.0 |
DNA-Binding Proteins/genetics | 7 | 0.0 |
Embryonic and Fetal Development/genetics | 7 | 7.0 |
Microsatellite Repeats/genetics | 2 | 0.0 |
Mutation/genetics | 4 | 0.0 |
*Transcription Factors | 5 | 0.0 |
Cell Size | 2 | 0.0 |
*Embryonic and Fetal Development | 4 | 3.0 |
Genes, Structural | 4 | 0.0 |
Insulin-Like Growth Factor II/genetics/metabolism | 4 | 44.0 |
Receptor, IGF Type 2/genetics/metabolism | 2 | 66.0 |
Signal Transduction/physiology | 4 | 0.0 |
Gestational Age | 5 | 0.0 |
Infant, Newborn | 15 | 0.0 |
Chimera | 4 | 2.0 |
Crosses, Genetic | 11 | 1.0 |
Fibroblasts/cytology/physiology | 2 | 2.0 |
*Gene Expression Regulation | 10 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Nephroblastoma/*genetics | 13 | 8.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Beckwith-Wiedemann Syndrome/*genetics/pathology | 2 | 100.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Nuclear Proteins/*genetics | 8 | 1.0 |
Beckwith-Wiedemann Syndrome/*genetics | 26 | 59.0 |
*Gene Deletion | 3 | 0.0 |
*ATP-Binding Cassette Transporters | 2 | 1.0 |
*Chromosomes, Human, Pair 11 | 27 | 4.0 |
Gene Dosage | 2 | 0.0 |
Hyperplasia | 4 | 1.0 |
Insulin-Like Growth Factor II/biosynthesis/genetics | 5 | 71.0 |
*Potassium Channels, Inwardly Rectifying | 2 | 4.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Autoantigens/*genetics | 3 | 4.0 |
Japan | 2 | 0.0 |
Membrane Proteins/*genetics | 3 | 0.0 |
*Organic Cation Transport Proteins | 2 | 7.0 |
Colorectal Neoplasms/*genetics | 6 | 2.0 |
Cross-Sectional Studies | 3 | 0.0 |
Disease Models, Animal | 7 | 0.0 |
Blotting, Northern | 12 | 0.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
*Gene Expression Regulation, Developmental | 8 | 1.0 |
Insulin-Like Growth Factor II/biosynthesis/*genetics | 16 | 88.0 |
Multigene Family | 10 | 1.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
Sequence Analysis, DNA | 7 | 0.0 |
Carcinoma, Hepatocellular/*genetics/metabolism | 3 | 15.0 |
Fathers | 9 | 15.0 |
Mothers | 8 | 9.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/*genetics | 6 | 3.0 |
*Genes, Regulator | 2 | 1.0 |
Genetic Predisposition to Disease | 8 | 0.0 |
Neoplasm Proteins/genetics | 3 | 0.0 |
Species Specificity | 7 | 0.0 |
DNA/analysis | 2 | 0.0 |
Haplotypes | 3 | 0.0 |
Minisatellite Repeats/*genetics | 4 | 5.0 |
Age Factors | 3 | 0.0 |
Aging/*genetics | 2 | 3.0 |
CpG Islands | 2 | 0.0 |
Neoplasms/*genetics | 4 | 1.0 |
Gene Expression Regulation, Developmental | 19 | 1.0 |
Mice, Inbred Strains | 3 | 0.0 |
Sequence Deletion/genetics | 2 | 1.0 |
Muscle Proteins/biosynthesis/genetics | 5 | 25.0 |
Muscle Proteins/genetics | 14 | 20.0 |
Rhabdomyosarcoma/*genetics | 5 | 23.0 |
Transcription Factors/genetics | 8 | 0.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Chromosome Aberrations | 3 | 0.0 |
Chromosome Disorders | 2 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 13 | 6.0 |
Germ-Line Mutation | 3 | 0.0 |
Muscle Proteins/genetics/physiology | 2 | 40.0 |
Transcription Factors | 3 | 3.0 |
Zinc Fingers | 4 | 0.0 |
*Biological Markers | 2 | 1.0 |
Microsatellite Repeats/*genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Drug Synergism | 2 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Hydroxamic Acids/*pharmacology | 2 | 4.0 |
Kidney/metabolism | 3 | 0.0 |
Methylation | 15 | 2.0 |
Models, Genetic | 8 | 0.0 |
Karyotyping | 11 | 0.0 |
Fibroblasts | 3 | 0.0 |
Muscle Proteins/*genetics/metabolism | 6 | 30.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Muscle Proteins/*genetics | 25 | 16.0 |
Protein Binding | 5 | 0.0 |
Transcription Factors/*physiology | 2 | 0.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 22 | 0.0 |
Enhancer Elements (Genetics)/*genetics | 2 | 2.0 |
Organ Specificity/genetics | 3 | 2.0 |
Blotting, Southern | 9 | 0.0 |
Fetus | 13 | 2.0 |
Protein Conformation | 2 | 0.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Receptors, Somatomedin/genetics | 2 | 40.0 |
Somatomedins/*genetics | 6 | 40.0 |
Liver Neoplasms/*genetics/pathology | 2 | 8.0 |
Embryo | 2 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Mice, Inbred CBA | 3 | 0.0 |
*Drosophila Proteins | 2 | 0.0 |
Kidney Neoplasms/*genetics | 10 | 4.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
WT1 Proteins | 4 | 1.0 |
DNA, Neoplasm/genetics | 6 | 0.0 |
Polymerase Chain Reaction/methods | 6 | 0.0 |
Exons | 12 | 0.0 |
Lung Neoplasms/*genetics | 4 | 1.0 |
Embryo/metabolism | 2 | 1.0 |
Kidney/embryology | 2 | 6.0 |
Proteins/*genetics/metabolism | 2 | 0.0 |
Mosaicism | 2 | 2.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Insulin-Like Growth Factor I/*metabolism | 3 | 2.0 |
Insulin-Like Growth Factor II/metabolism | 4 | 14.0 |
Genetic Screening | 2 | 0.0 |
Growth Disorders/*genetics | 4 | 7.0 |
Syndrome | 6 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Response Elements/genetics | 2 | 1.0 |
Haplotypes/genetics | 3 | 0.0 |
Introns/genetics | 2 | 0.0 |
Potassium Channels/genetics | 4 | 8.0 |
Receptor, IGF Type 2/genetics | 5 | 20.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Disease Progression | 3 | 0.0 |
Chromosome Deletion | 4 | 0.0 |
Hematopoietic Stem Cells/metabolism | 2 | 1.0 |
In Situ Hybridization | 20 | 0.0 |
Frameshift Mutation | 2 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Gene Library | 3 | 0.0 |
*Insulin-Like Growth Factor Binding Proteins | 2 | 16.0 |
Muridae | 3 | 2.0 |
Kidney/physiology | 3 | 5.0 |
Beckwith-Wiedemann Syndrome/embryology/*genetics/pathology | 2 | 100.0 |
Bone and Bones/abnormalities/embryology | 2 | 33.0 |
Fetal Death/genetics | 3 | 14.0 |
Genes, Lethal | 2 | 2.0 |
Genetic Heterogeneity | 2 | 0.0 |
Insulin-Like Growth Factor II/*genetics/physiology | 3 | 100.0 |
Kidney/embryology/pathology | 2 | 66.0 |
Mice, Knockout | 6 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
Receptor, IGF Type 2/metabolism | 2 | 9.0 |
Insulin-Like Growth Factor I/metabolism | 2 | 1.0 |
Protein-Tyrosine Kinase/genetics | 2 | 1.0 |
Mammals | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
*Genes, Wilms Tumor | 6 | 3.0 |
Leiomyoma/*genetics | 3 | 15.0 |
Uterine Neoplasms/*genetics | 4 | 10.0 |
Chromosomes/*genetics | 2 | 2.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Kidney/pathology | 3 | 2.0 |
Rats, Inbred BN | 3 | 6.0 |
Trisomy | 3 | 2.0 |
Breast Neoplasms/*genetics | 4 | 0.0 |
RNA, Neoplasm/genetics | 6 | 1.0 |
*Membrane Proteins | 6 | 0.0 |
Muscle Proteins/biosynthesis/*genetics | 3 | 30.0 |
Fibroblasts/physiology | 2 | 1.0 |
Introns | 2 | 0.0 |
Nephroblastoma/genetics | 12 | 21.0 |
Potassium Channels/biosynthesis/*genetics | 2 | 40.0 |
Blotting, Western | 3 | 0.0 |
Carrier Proteins/*genetics/metabolism | 2 | 0.0 |
Cell Division/*physiology | 2 | 1.0 |
Polymorphism, Single-Stranded Conformational | 4 | 0.0 |
Receptor, IGF Type 2/*genetics | 4 | 13.0 |
Animals, Newborn | 2 | 0.0 |
Embryo/physiology | 2 | 5.0 |
Sheep/*genetics | 3 | 5.0 |
Growth Substances/*metabolism | 2 | 1.0 |
Nerve Tissue Proteins/*genetics/metabolism | 2 | 2.0 |
Germinoma/*genetics | 3 | 21.0 |
Muscle Proteins/analysis/*genetics | 2 | 33.0 |
Fetus/metabolism | 5 | 3.0 |
RNA/genetics/metabolism | 2 | 1.0 |
Tissue Distribution | 3 | 0.0 |
Somatomedins/*analysis | 2 | 18.0 |
Kinetics | 3 | 0.0 |
Metaphase | 2 | 1.0 |
Mice/genetics | 3 | 5.0 |
Risk Factors | 6 | 0.0 |
Genes, Tumor Suppressor/genetics | 6 | 3.0 |
*Heparan Sulfate Proteoglycan | 3 | 10.0 |
Choriocarcinoma/*genetics | 2 | 22.0 |
Hydatidiform Mole/*genetics | 2 | 25.0 |
Insulin-Like Growth Factor II/*biosynthesis/genetics | 8 | 57.0 |
Breast/*metabolism | 2 | 3.0 |
Fibroblasts/metabolism | 3 | 0.0 |
Insulin-Like Growth Factor II/*metabolism | 4 | 15.0 |
Histones/*metabolism | 2 | 1.0 |
*X Chromosome | 2 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Insulin-Like Growth Factor II/*biosynthesis | 3 | 75.0 |
Cell Culture Techniques | 2 | 0.0 |
RNA, Messenger/genetics | 7 | 0.0 |
Gene Deletion | 6 | 0.0 |
Placenta/*metabolism | 5 | 3.0 |
Promoter Regions (Genetics)/genetics | 5 | 0.0 |
Beckwith-Wiedemann Syndrome/genetics | 5 | 23.0 |
Kidney Neoplasms/genetics | 6 | 8.0 |
CpG Islands/*genetics | 2 | 2.0 |
Liver/*embryology | 2 | 13.0 |
Deoxyribonucleases, Type II Site-Specific/genetics | 2 | 4.0 |
Kidney Neoplasms/genetics/metabolism | 2 | 16.0 |
Embryonic and Fetal Development/*genetics | 5 | 6.0 |
Exons/genetics | 2 | 0.0 |
Placenta/metabolism | 3 | 1.0 |
Chronic Disease | 2 | 0.0 |
Pancreas/embryology | 2 | 66.0 |
Transcription Factors/biosynthesis/genetics | 2 | 2.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Insulin-Like Growth Factor II/*biosynthesis/*genetics | 3 | 100.0 |
*Chromosome Deletion | 4 | 0.0 |
Dinucleotide Repeats | 2 | 2.0 |
Insulin-Like Growth Factor I/*biosynthesis/genetics | 2 | 33.0 |
RNA, Messenger | 2 | 0.0 |
Receptor, IGF Type 1/*biosynthesis/genetics | 2 | 50.0 |
Receptor, IGF Type 2/*biosynthesis/genetics | 2 | 100.0 |
Fetus/physiology | 3 | 6.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Carcinoma, Renal Cell/*genetics/metabolism | 2 | 13.0 |
Kidney Neoplasms/*genetics/metabolism | 5 | 18.0 |
Chimera/*genetics | 2 | 18.0 |
Chromosomes | 2 | 2.0 |
Sarcoma, Clear Cell/*genetics/pathology | 2 | 66.0 |
*Polymorphism, Genetic | 7 | 0.0 |
DNA Primers/genetics | 5 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
*Heterozygote | 2 | 0.0 |
Beckwith-Wiedemann Syndrome/enzymology/*genetics | 2 | 50.0 |
Dinucleoside Phosphates | 2 | 11.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Genes, Wilms Tumor/*genetics | 3 | 4.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Blastocyst/*metabolism | 2 | 8.0 |
Testicular Neoplasms/*genetics | 2 | 8.0 |
*Chromosome Aberrations | 3 | 0.0 |
Epistasis, Genetic | 2 | 3.0 |
Translocation, Genetic/genetics | 3 | 3.0 |
Deoxyribonucleases, Type II Site-Specific | 3 | 1.0 |
Nephroblastoma/*genetics/metabolism | 3 | 21.0 |
Growth/genetics | 3 | 30.0 |
Prader-Willi Syndrome/*genetics | 2 | 2.0 |
Breast Neoplasms/genetics | 2 | 0.0 |
Lung Neoplasms/genetics | 2 | 3.0 |
DNA | 3 | 0.0 |
*Genetic Markers | 3 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Rats, Inbred Lew | 2 | 0.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Insulin-Like Growth Factor II/*genetics/*metabolism | 2 | 66.0 |
Rhabdomyosarcoma/genetics | 2 | 15.0 |
Insulin-Like Growth Factor II/genetics/*metabolism | 3 | 75.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Biopsy | 2 | 0.0 |
Multigene Family/*genetics | 2 | 1.0 |
Cattle | 3 | 0.0 |
Repetitive Sequences, Nucleic Acid | 4 | 0.0 |
Chromosomes, Human, Pair 1 | 2 | 0.0 |
Translocation, Genetic | 4 | 0.0 |
*Diploidy | 2 | 9.0 |
Myometrium/metabolism | 2 | 8.0 |
*Genes, Structural | 3 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Fetus/chemistry | 2 | 12.0 |
*Point Mutation | 2 | 0.0 |
Liver/*metabolism | 2 | 0.0 |
Insulin-Like Growth Factor II/*analysis | 2 | 18.0 |
RNA/biosynthesis/*genetics | 2 | 66.0 |
Hydatidiform Mole/genetics | 2 | 33.0 |
Placenta/*physiology | 2 | 7.0 |
DNA Probes | 4 | 0.0 |
Liver/embryology/metabolism | 2 | 6.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
Seminoma/genetics | 2 | 28.0 |
Incidence | 2 | 0.0 |
Genes, ras | 2 | 0.0 |
Microscopy, Electron/methods | 2 | 3.0 |
Beckwith-Wiedemann Syndrome/complications/*genetics | 2 | 50.0 |
Ovarian Neoplasms/genetics | 2 | 1.0 |
Teratoma/genetics | 2 | 28.0 |
Parents | 3 | 4.0 |
Receptor, IGF Type 2/biosynthesis/*genetics | 2 | 66.0 |
Kidney/embryology/metabolism | 2 | 5.0 |
*Polymorphism, Restriction Fragment Length | 5 | 0.0 |
DNA, Single-Stranded | 2 | 2.0 |
Dosage Compensation (Genetics) | 2 | 1.0 |
Gene Expression Profiling/methods | 3 | 4.0 |
Receptors, Somatomedin | 4 | 9.0 |
Chromosome Banding | 2 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Hybrid Cells/cytology | 2 | 6.0 |
Cell Count | 2 | 0.0 |
*Proto-Oncogenes | 2 | 0.0 |
Genomic Imprinting/*physiology | 3 | 50.0 |
Breast Neoplasms/*analysis | 2 | 5.0 |
Somatomedins/*metabolism | 2 | 8.0 |
DNA Restriction Enzymes | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
Gene Expression/physiology | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Odds Ratio | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
